Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
- PMID: 8839686
- DOI: 10.1007/BF03190261
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
Abstract
Genetic and environmental factors are determinants of the interindividual and interethnic variability in drug metabolism. The metabolism of several important drugs (e.g. haloperidol) cosegregates with that of debrisoquine. Thus, interethnic differences in debrisoquine hydroxylation polymorphism (CYP2D6) might be partly responsible for the variation in haloperidol disposition between races. The influence of tobacco, ethanol, caffeine, gender, and oral contraceptive use on the debrisoquine metabolic ratio (MR) has been analyzed in 633 Spanish healthy volunteers. MR was also determined in panels of healthy volunteers. 18 smokers were studied during a tobacco abstinence period, and 31 women three times during the same menstrual cycle. Among EMs, debrisoquine MR was significantly (P < 0.05) lower during smoking cessation (mean antilog +/- SD, 0.48 +/- 0.29) compared to a smoking period (0.61 +/- 0.23). During the lutheal phase of the menstrual cycle, debrisoquine MR was also significantly (P < 0.01) lower (0.33 +/- 0.41) compared to the ovulatory-phase (0.41 +/- 0.34) and the phase before ovulation (0.44 +/- 0.36). Among EMs, it is suggested that debrisoquine MR may be modified by tobacco smoking and sexual hormones. The clinical relevance of these findings remains unclear.
Similar articles
-
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.Pharmacogenomics. 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. Pharmacogenomics. 2009. PMID: 19102711 Review.
-
Debrisoquine hydroxylation in a Polish population.Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702. Eur J Clin Pharmacol. 1995. PMID: 7768252
-
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.J Pharmacol Exp Ther. 1995 Jul;274(1):516-20. J Pharmacol Exp Ther. 1995. PMID: 7616439
-
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.Pharmacogenomics J. 2012 Apr;12(2):176-83. doi: 10.1038/tpj.2010.85. Epub 2010 Dec 7. Pharmacogenomics J. 2012. PMID: 21135868
-
[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Psychiatr Pol. 1995 Jan-Feb;29(1):57-66. Psychiatr Pol. 1995. PMID: 7878155 Review. Polish.
Cited by
-
QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.Eur J Clin Pharmacol. 2002 Jun;58(3):223-24. doi: 10.1007/s00228-002-0452-7. Eur J Clin Pharmacol. 2002. PMID: 12162273 Clinical Trial. No abstract available.
-
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28. Eur J Clin Pharmacol. 2003. PMID: 12682803 Clinical Trial.
-
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.Clin Pharmacokinet. 2004;43(14):983-1013. doi: 10.2165/00003088-200443140-00003. Clin Pharmacokinet. 2004. PMID: 15530129 Review.
-
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.Br J Clin Pharmacol. 2001 Feb;51(2):169-73. doi: 10.1111/j.1365-2125.2001.01328.x. Br J Clin Pharmacol. 2001. PMID: 11259990 Free PMC article. Clinical Trial.
-
Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.